81 results
S-8
EX-4
REPCF
Replicel Life Sciences Inc.
6 Oct 06
Registration of securities for employees
12:00am
with the Company or any Related Company for any reason whatsoever other than cause, death or Disability (as defined below); or
the expiration of one year (1 … ) from termination of an Optionee's employment or contractual relationship by reason of death or Disability (as defined below).
(ii)
Upon the death
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
their successors are duly elected or appointed in accordance with the Company's articles or until such director's earlier death, resignation or removal … .
Cessation of Employment
If an Optionee ceases to be an Eligible Person, his or her Option shall be exercisable as follows:
- 14 -
(a) Death
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
9 Aug 23
Statement of Executive Compensation
7:41pm
of Employment
If an Optionee ceases to be an Eligible Person, his or her Option shall be exercisable as follows:
(a) Death or Disability …
If the Optionee ceases to be an Eligible Person, due to his or her death or Disability or, in the case of an Optionee that is a company, the death or Disability
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
7 Jul 22
Statement of Executive Compensation
1:43pm
of termination for cause or by resignation.
If an option holder ceases to be a director, employee or consultant of the Company (other than by reason of death … representatives, heirs or executors may exercise any option granted to the option holder that had vested and was exercisable on the date of death until
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Jun 22
Statement of Executive Compensation
11:16am
of termination for cause or by resignation.
If an option holder ceases to be a director, employee or consultant of the Company (other than by reason of death … representatives, heirs or executors may exercise any option granted to the option holder that had vested and was exercisable on the date of death until
6-K
939fab q6x
24 Nov 10
Current report (foreign)
12:00am
S-8
EX-4
9zrgch4t8q0lx5u
6 Oct 06
Registration of securities for employees
12:00am
6-K
EX-3
ej6ob5s7cf 0c
2 Jul 03
Current report (foreign)
12:00am
6-K
EX-99.1
v22a4icnd9cv3s1
23 Jul 15
RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
12:00am
6-K
EX-99.1
qk211n czwj
6 Nov 19
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
lxhmom8 joh
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.1
339qwq85
22 Jan 19
Current report (foreign)
4:43pm
6-K
EX-99.5
ubi3b
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
20-F
79kkkfb
27 Jun 03
Annual report (foreign)
12:00am
20FR12G/A
j3ke74zc
13 Jan 03
Initial registration of securities (foreign private issuers) (amended)
12:00am